Belgian College of Neuropsychopharmacology and Biological Psychiatry 

Jacqueline Scuvée-Moreau


SCUVÉE-MOREAU J., LIÉGEOIS J.F., MASSOTTE L. and SEUTIN V. Methyl-laudanosine: a new pharmacological tool to investigate the function of small conductance Ca2+-activated K+ (SK) channels. J Pharmacol Exp Ther, 302, n° 2, 1176-1183, 2002. :

SCUVEE-MOREAU J., KURZ X., DRESSE A. and the NADES Group. The economic impact of demential in Belgium: results of the National Dementia Economic Study (NADES). Acta neurol. Belg., 102, 104-113, 2002. :  

LIEGEOIS J.-F., MERCIER F., GRAULICH A., GRAULICH-LORGE F., SCUVEE-MOREAU J. and SEUTIN V. Modulation of small conductance calcium-activated potassium (SK) channels : a new challenge in medicinal chemistry. Curr Med Chem 10 (8), 625-647, 2003. :;

KURZ X., SCUVEE-MOREAU J., VERNOOIJ-DASSEN M., DRESSE A. and the NADES Group. Cognitive impairment, dementia and quality of life. Acta neurol. belg., 103, 24-34, 2003.

VERNOOIJ-DASSEN M., KURZ X., SCUVEE-MOREAU J. and DRESSE A. La mesure du sentiment de compétence chez les aidants de patients déments. Rev Epidémiol Sante Publique 51, 227-235, 2003

KURZ X., SCUVEE-MOREAU J., RIVE B. and DRESSE A. A new approach to the qualitative evaluation of functional disability in dementia. Int J Geriatr Psychiatry 18, 1050-1055, 2003.

SCUVEE-MOREAU J,  BOLAND A, GRAULICH A, VAN OVERMEIRE L, D’HOEDT D, GRAULICH-LORGE F, THOMAS E, ABRAS A, STOCKER M, LIEGEOIS J-F and SEUTIN V. Electrophysiological characterization of the SK channel blockers methyl-laudanosine and methyl-noscapine in cell lines and rat brain slices. Br. J Pharmacol. 143, 753-764, 2004.,

GRAULICH A, MERCIER F, SCUVEE-MOREAU J, SEUTIN V and LIEGEOIS J.-F. ,Synthesis and Biological Evaluation of N-Methyl-Laudanosine Iodide Analogues as Potential SK Channel Blockers. Bioorg. Med. Chem. Vol 13/4 pp 1201-1209, 2005;

GRAULICH A , SCUVEE-MOREAU J, SEUTIN V and LIEGEOIS J-F. Synthesis and Radioligand Binding Studies of C-5 and C-8 Substituted 1-(3,4-Dimethoxybenzyl)-2,2-Dimethyl-1,2,3,4-tetrahydroisoquinoliniums as SK Channel Blockers Related to N-Methyl-Laudanosine and N-Methyl-Noscapine. J. Med. Chem. 48, 4972-4982, 2005 :;  

WAROUX O, MASSOTTE L, ALLEVA L, GRAULICH A, THOMAS E, LIEGEOIS J-F, SCUVEE-MOREAU J and SEUTIN V. SK channels control the firing pattern of midbrain dopaminergic neurons in vivo. European Journal of Neuroscience, vol 22, issue 12, 3111- 3121, 2005.;

HANSEN HH, EBBESEN C, MATHIESEN C, WEIKOP P, RONN LC, WAROUX O, SCUVEE-MOREAU J, SEUTIN V and MIKKELSEN JD. The KCNQ opener Retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J Pharmacol Exp Ther 318, 1006-1019, 2006;

GRAULICH A, SCUVEE-MOREAU J, ALLEVA L, LAMY C, WAROUX O, SEUTIN V and LIEGEOIS J-F. Synthesis and radioligand binding studies of methoxylated 1,2,3,4-tetrahydroisoquinolinium derivatives as ligands of the apamin-sensitive Ca2+- activated K+ channels , J Med Chem 49, 7208-7214, 2006  

ANDRIEU S, RIVE B, GUILHAUME C, KURZ X, SCUVEE-MOREAU J, GRAND A and DRESSE A. New assessment of dependency in demented patients: impact on the quality of life in informal caregivers. Psychiatry and Clinical Neurosciences 61 (3), 234–242, 2007

GRAULICH A, DILLY S, FARCE A, SCUVEE-MOREAU J, WAROUX O, LAMY C, CHAVATTE P, SEUTIN V, LIEGEOIS J-F Synthesis and radioligand binding studies of bis-isoquinolinium derivatives as small conductance Ca2+-activated K+ channel blockers  J Med Chem 2007, 50, 5070 - 5075

DEFRAITEUR C., PLENEVAUX A., SCUVEE-MOREAU J., ROUCHET N., GOBLET D, LUXEN A. and SEUTIN V. Characterization of 4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine (p-DMPPF) as a new potent 5-HT1A antagonist. Br J Pharmacol  152, 952-958, 2007  

PHAN-BA R., SCUVEE-MOREAU J and SEUTIN V. Stratégies pharmacologiques de modulation de l'activité du système nerveux central. Rev Méd Liège vol 63, 5-6, 238-244, 2008  

ROUCHET N., WAROUX O., LAMY C., MASSOTTE L., SCUVEE-MOREAU J., LIEGEOIS J.-F. and SEUTIN V. SK channel blockade promotes burst firing in dorsal raphe serotonergic neurons. European J Neuroscience, vol 28, 1108-1115, 2008.

DRION G, BONJEAN M, WAROUX O, SCUVEE-MOREAU J, LIEGEOIS JF, SEJNOWSKI TJ, SEPULCHRE R, SEUTIN V. M-type channels selectively control bursting in rat dopaminergic neurons Eur J Neurosci. 31, 827-835, 2010  

LAMY C*, SCUVEE-MOREAU J*, DILLY S, LIEGEOIS J-F, SEUTIN V. The sigma agonist 1,3-di-o-tolylguanidine directly blocks SK channels in dopaminergic neurons and in cell lines. Eur J Pharmacol 641, 23-8. 2010

•    *co-1ers auteurs

Sébastien Dilly, Jacqueline Scuvée-Moreau, Johan Wouters, Jean-François Liégeois The 5-HT1A agonism potential of substituted-piperazine-ethyl-amide derivatives is conserved in the hexyl homologues: molecular modeling and pharmacological evaluation in Journal of Chemical Information and Modeling 51, 2961-2966, 2011

F Mangin, S Dilly, B Joly, J Scuvée-Moreau, J Evans, V Setola, B Roth, J-F Liégeois. Moderate chemical modulations of WAY100635 improve the selectivity for 5-HT1A versus D4 receptors Bioorganic & Medicinal Chemistry Letters, 22, 4550-4554, 2012


Print Email


UPC KU Leuven, Campus Gasthuisberg,
Herestraat 49,
3000 Leuven

VAT BE 0415.048.548

BE40 2900 1349 6963 
BNP Paribas Fortis